Nyxoah S A (NYXH) Stock Price, Quote & News

Company Profile

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 32 1 022 23 55

Fax: 32 1 045 90 75

Website: www.nyxoah.com

Address:

Rue Edouard Belin 12, Mont-Saint-Guibert, Belgium

KingTut Aug. 19 at 10:27 AM

$NYXH 6.02 euro in Brussels that's over $7. 6.88 x 7.08 currently in pm .

0 · Reply

Joe5280 Aug. 18 at 11:24 PM

$NYXH Don't fall for it... !!! Today was Earnings report today... bad news ...

1 · Reply

KingTut Aug. 18 at 9:12 PM

$NYXH 25K per device. if they get 1000 patients , we are at 25mil in revenue. mcap for this is 200m. To compare $INSP had sales of more than 200m this past Q, for arguably a not as good a product . Might take some time, but this has a potential of a 100-200% gain in a year or so.

1 · Reply

KingTut Aug. 15 at 7:55 PM

$NYXH ok a small buy 6.19.

0 · Reply

shilldo Aug. 14 at 5:32 PM

$IXHL not way $NYXH has a higher mcap than $IXHL - solving the same problem albeit differently. They may be further in the pipe but $IXHL should be applying for fast track status soon… I wonder why they are waiting on that… hmmm

0 · Reply

Joe5280 Aug. 11 at 10:34 PM

$NYXH Time to file some claims/complaints with SCC and law firms!

0 · Reply

Joe5280 Aug. 11 at 10:32 PM

$NYXH If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] www.schallfirm.com

0 · Reply

Joe5280 Aug. 11 at 10:30 PM

$NYXH part 2: Following Nyxoah's announcement, analysts projected that Genio's commercial launch would be delayed pending further review by the FDA. Following this news, Nyxoah's stock price fell over 21% on March 26, 2025. To obtain additional information, go to: https://zlk.com/pslra-1/nyxoah-s-a-lawsuit-submission-form?prid=139220&wire=1 or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212)363-7500.

0 · Reply

Joe5280 Aug. 11 at 10:29 PM

$NYXH ON Shit... this is a repeat of what they did in March... check it out!!! NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Nyxoah S.A. ("Nyxoah S.A.") (NASDAQ:NYXH) concerning possible violations of federal securities laws. Nyxoah issued a press release on March 25, 2025, "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA) application for the Genio® system", which "means that Nyxoah's application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA's PMA implementing regulations . . . , and the FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review." Cont....

0 · Reply

Joe5280 Aug. 11 at 10:25 PM

$NYXH Something is definitely not right... FDA Approval... NO Volume and loses market cap... this smells of some serious manipulation!! Unbelievable!!!!!!!!

0 · Reply

Nyxoah: High-Risk High-Reward Medtech To Own

Aug 18, 2025, 7:07 PM EDT - 8 days ago

Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript

Aug 18, 2025, 4:10 PM EDT - 8 days ago

Nyxoah Reports Second Quarter Financial and Operating Results

Aug 11, 2025, 1:00 AM EDT - 16 days ago

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Aug 8, 2025, 4:10 PM EDT - 18 days ago

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

Jul 29, 2025, 4:30 PM EDT - 4 weeks ago

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025

Jul 28, 2025, 4:05 PM EDT - 4 weeks ago

Nyxoah's DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

Jun 13, 2025, 1:00 AM EDT - 2 months ago

Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025

May 28, 2025, 4:30 PM EDT - 3 months ago

Nyxoah to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 2:35 PM EDT - 3 months ago

Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:00 AM EDT - 3 months ago

Nyxoah Reports First Quarter Financial and Operating Results

May 9, 2025, 4:30 PM EDT - 3 months ago

Publication relating to transparency notifications

May 9, 2025, 1:00 AM EDT - 3 months ago

Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 11, 2025

Apr 22, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Shareholders to Reach Out

Apr 21, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Shareholders to Learn More About the Investigation

Apr 20, 2025, 10:00 AM EDT - 4 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 18, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Shareholders to Inquire about Securities Investigation

Apr 17, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Investors to Connect

Apr 16, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Stockholders to Inquire about Securities Investigation

Apr 16, 2025, 2:00 AM EDT - 4 months ago

Conditional Issuance of Shares

Apr 15, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Investors to Learn More About the Investigation

Apr 14, 2025, 10:00 AM EDT - 4 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 11, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Stockholders to Connect

Apr 10, 2025, 10:00 AM EDT - 4 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 9, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Stockholders to Learn More About the Investigation

Apr 8, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Investors to Inquire about Securities Investigation

Apr 8, 2025, 1:00 AM EDT - 5 months ago

Nyxoah Provides Update on FDA Approvable Letter for Genio System

Apr 7, 2025, 3:00 PM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Investors to Reach Out

Apr 7, 2025, 9:33 AM EDT - 5 months ago

NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law Firm

Mar 31, 2025, 5:40 PM EDT - 5 months ago

Nyxoah S.A. Investors: Company Investigated by the Portnoy Law Firm

Mar 31, 2025, 2:45 PM EDT - 5 months ago

Nyxoah S.A. Being Investigated on Behalf of Nyxoah S.A.

Mar 26, 2025, 3:00 AM EDT - 5 months ago

FDA Issues Nyxoah an Approvable Letter for its Genio® System

Mar 13, 2025, 4:45 PM EDT - 5 months ago

Nyxoah SA (NYXH) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 2:00 AM EDT - 5 months ago

Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results

Mar 10, 2025, 5:05 PM EDT - 6 months ago

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

Mar 3, 2025, 4:30 PM EST - 6 months ago

Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Feb 19, 2025, 1:05 AM EST - 6 months ago

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

Dec 30, 2024, 4:01 AM EST - 8 months ago

Nyxoah: The Future Of OSA

Dec 13, 2024, 2:05 AM EST - 9 months ago

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Nov 20, 2024, 4:05 PM EST - 9 months ago

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 1:00 AM EST - 10 months ago

Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024

Nov 8, 2024, 6:46 PM EST - 10 months ago

Nyxoah S.A. (NYXH) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:45 PM EST - 10 months ago

Nyxoah Appoints John Landry as Chief Financial Officer

Oct 22, 2024, 4:30 PM EDT - 11 months ago

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

Oct 7, 2024, 5:00 PM EDT - 11 months ago

Nyxoah Raises $27 Million through its At-the-Market Offering

KingTut Aug. 19 at 10:27 AM

$NYXH 6.02 euro in Brussels that's over $7. 6.88 x 7.08 currently in pm .

0 · Reply

Joe5280 Aug. 18 at 11:24 PM

$NYXH Don't fall for it... !!! Today was Earnings report today... bad news ...

1 · Reply

KingTut Aug. 18 at 9:12 PM

1 · Reply

KingTut Aug. 15 at 7:55 PM

$NYXH ok a small buy 6.19.

0 · Reply

shilldo Aug. 14 at 5:32 PM

0 · Reply

Joe5280 Aug. 11 at 10:34 PM

$NYXH Time to file some claims/complaints with SCC and law firms!

0 · Reply

Joe5280 Aug. 11 at 10:32 PM

0 · Reply

Joe5280 Aug. 11 at 10:30 PM

0 · Reply

Joe5280 Aug. 11 at 10:29 PM

0 · Reply

Joe5280 Aug. 11 at 10:25 PM

$NYXH Something is definitely not right... FDA Approval... NO Volume and loses market cap... this smells of some serious manipulation!! Unbelievable!!!!!!!!

0 · Reply

WBT614 Aug. 11 at 9:21 PM

$NYXH boggles my mind how a stock w fda approval lose market cap. If anyone wants to educate me, please do.

2 · Reply

Sophie2025 Aug. 11 at 3:38 PM

$NYXH am I going to be a bag holder or is there any chance this is going to bounce back up? I am in -10% 🙄

1 · Reply

Culby Aug. 11 at 2:57 PM

$NYXH keep going!

0 · Reply

coletrain89 Aug. 11 at 1:47 PM

$NYXH seeing what is happening

0 · Reply

FlippinLinknz Aug. 11 at 1:26 PM

$NYXH Took a bit , good start.

0 · Reply

OpenOutcrier Aug. 11 at 12:38 PM

$NYXH (+11.9% pre) FDA Approves Nyxoah's Revolutionary Sleep Apnea Device While Inspire Launches Patent Battle https://ooc.bz/l/73405

0 · Reply

BPharmCatalyst Aug. 11 at 12:27 PM

$ENTO announced definitive agreements with institutional investors for the purchase and sale of approximately $3 million in pre-funded and common warrants. The transaction was priced at the market under Nasdaq rules. $IOBT $BJDX $NYXH $AVTR See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/entero-therapeutics-ento-warrants-io-biotech-iobt-phase-3-data

0 · Reply

coletrain89 Aug. 11 at 12:23 PM

$NYXH let's see what happens

0 · Reply

Joe5280 Aug. 11 at 11:55 AM

$NYXH Its like it stalled.. No volume... pretty surprising there is no action with an FDA approval... lets see what happens as RH opens in a few minutes

0 · Reply

Kuncheiyng Aug. 11 at 11:53 AM

$NYXH How much will the price end up being today?

0 · Reply

Lofticus Aug. 11 at 11:30 AM

$NYXH I see why it dropped for now. Shorts

0 · Reply

FlippinLinknz Aug. 11 at 11:04 AM

$NYXH Nice start.

0 · Reply

Market Cap	219.86M
Revenue (ttm)	4.89M
Net Income (ttm)	-64.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,310.84%
Debt to Equity Ratio	0.26

Volume	24,000
Avg Vol	89,122
Day's Range	N/A - N/A
Shares Out	34.06M
Stochastic %K	41%
Beta	1.61
Analysts	Strong Sell
Price Target	$12.75